
OCS Stock Forecast & Price Target
OCS Analyst Ratings
Bulls say
Oculis Holding is poised for success with its diversified ophthalmology pipeline targeting poorly-served areas of ophthalmic and retinal diseases, including DME, DED, and AON. With positive outcomes in Phase 1 of its DIAMOND and OPTIMIZE-1 clinical trials, the company is confident in the potential of its flagship product OCS-01 for the treatment of DME, which has a peak sales estimate of $1.2 billion in 2035. Additionally, Oculis is also advancing its topical anti-TNF biologic OCS-02 for DED and its neuroprotective agent OCS-05 for AON and other neurodegenerative conditions, each with blockbuster potential if successful. The company also has a strong financial position with pro-forma cash of $292 million, providing runway into 2029.
Bears say
Oculis Holding is a biopharmaceutical company with a negative outlook due to several factors. First, although the completion of the Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema (DME) is a positive development, the reported data will not be available until June 2026. Additionally, there is no guarantee that the trial results will support FDA approval. Furthermore, there are risks associated with the development and regulatory process, as well as the uptake and differentiation of OCS-01 and OCS-02 in their respective indications. These factors could impact the success and market penetration of Oculis Holding's potential products, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.
OCS Analyst Forecast & Price Prediction
Start investing in OCS
Order type
Buy in
Order amount
Est. shares
0 shares